71 related articles for article (PubMed ID: 19774737)
1. Chronic myelogenous leukemia: the new paradigm.
Winn RJ
J Natl Compr Canc Netw; 2003 Oct; 1(4):455. PubMed ID: 19774737
[No Abstract] [Full Text] [Related]
2. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
3. Control genes in international standardization of real-time RT-PCR for BCR-ABL.
Moravcová J; Rulcová J; Poláková KM; Klamová H
Leuk Res; 2009 Apr; 33(4):582-4. PubMed ID: 18653236
[No Abstract] [Full Text] [Related]
4. Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy.
Orciuolo E; Buda G; Galimberti S; Sordi E; Cervetti G; Petrini M
Cancer Genet Cytogenet; 2007 Sep; 177(2):166-7. PubMed ID: 17854678
[No Abstract] [Full Text] [Related]
5. Pathogenesis of chronic myelogenous leukemia.
Bergamaschi G; Rosti V
Haematologica; 1994; 79(1):1-3. PubMed ID: 15378940
[No Abstract] [Full Text] [Related]
6. Complex karyotype with a masked Philadelphia translocation and variant BCR-ABL fusion in CML.
Bakshi SR; Patel BP; Brahmbhatt MM; Trivedi PJ; Gajjar SB; Iyer RR; Parikh EH; Shukla SN; Shah PM
Cancer Genet Cytogenet; 2009 Mar; 189(2):142-3. PubMed ID: 19215799
[No Abstract] [Full Text] [Related]
7. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
8. Prevalence of the BCR/ABL1 transcripts in Mexican patients with chronic myelogenous leukemia.
Meza-Espinoza JP; Gutiérrez-Angulo M; Vázquez-Cárdenas A; Delgado-Lamas JL; Esparza-Flores MA; González-García JR
Rev Invest Clin; 2007; 59(5):338-41. PubMed ID: 18268888
[TBL] [Abstract][Full Text] [Related]
9. [Molecular detection of the BCR-ABL gen by RT-PCR in Costa Rican children with leukemia].
Jiménez-Arce G; Carrillo J; Chaves M; Jiménez R; Vargas M; Campos L; de la Guardia A; Valverde B
Rev Biol Trop; 2008 Dec; 56(4):1613-8. PubMed ID: 19419069
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous occurrence of variant Philadelphia translocations and ABL mutations in two patients with chronic myeloid leukemia.
Zhao Y; Wu G; Wu K; Liu L; Cao W; Yu X; Luo Y; Shi J; Tan Y; Huang H
Leuk Res; 2009 Jul; 33(7):e85-7. PubMed ID: 19203793
[No Abstract] [Full Text] [Related]
11. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
Beel K; Janssens A; Verhoef G; Vandenberghe P
Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL and CDKN2A: a dropped connection.
Williams RT; Sherr CJ
Nat Rev Cancer; 2008 Jul; 8(7):563; author reply 563. PubMed ID: 18574466
[No Abstract] [Full Text] [Related]
13. Chronic myelogenous leukemia, BCR-ABL1+.
Vardiman JW
Am J Clin Pathol; 2009 Aug; 132(2):250-60. PubMed ID: 19605820
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of chronic myeloid leukemia. Uncommon view of the modern approaches].
Mayer J; Zácková D; Klamová H; Doubek M
Cas Lek Cesk; 2008; 147(4):206-10. PubMed ID: 18578373
[TBL] [Abstract][Full Text] [Related]
16. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnosis of myeloproliferative neoplasms.
Patnaik MM; Tefferi A
Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
[TBL] [Abstract][Full Text] [Related]
18. Isotretinoin for juvenile chronic myelogenous leukemia.
Donadieu J
N Engl J Med; 1995 Jun; 332(22):1521. PubMed ID: 7739704
[No Abstract] [Full Text] [Related]
19. [Chronic myeloid leukemia in the 21st century: biology and treatment].
Chávez-González MA; Ayala-Sánchez M; Mayani H
Rev Invest Clin; 2009; 61(3):221-32. PubMed ID: 19736811
[TBL] [Abstract][Full Text] [Related]
20. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
